Zalcitabine是一种核苷类HIV逆转录酶抑制剂(NARTI)。
Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI).
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Coucke PA, et al. Cell line specific radiosensitizing effect of zalcitabine (2',3'-dideoxycytidine). Acta Oncol. 1997;36(2):199-205.
分子式 C9H13N3O3 |
分子量 211.22 |
CAS号 7481-89-2 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 45 mg/mL |
Water 76 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00002118 | HIV Infections | Drug: Zalcitabine | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT00002256 | HIV Infections | Drug: Zalcitabine | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT00002333 | HIV Infections | Drug: Saquinavir|Drug: Zalcitabine | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service | Phase 2 | 2005-06-23 | |
NCT00000653 | HIV Infections | Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche | Phase 2 | 2012-03-29 | |
NCT00000997 | HIV Infections | Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-03-15 | ||
NCT00000704 | HIV Infections | Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2012-03-15 | |
NCT00002265 | HIV Infections | Drug: Zalcitabine | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service | Phase 2 | 2005-06-23 | |
NCT00000719 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-03-28 | ||
NCT00001040 | HIV Infections | Drug: Saquinavir|Drug: Zidovudine|Drug: Zalcitabine | Hoffmann-La Roche|National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2011-02-28 | |
NCT00002081 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT00000651 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche|Glaxo Wellcome | Phase 3 | 2012-03-28 | |
NCT00000679 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche | Phase 2 | 2011-03-11 | |
NCT00002117 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service | Phase 3 | 2005-06-23 | |
NCT00000678 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche | Phase 2 | 2011-03-11 | |
NCT00000978 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche | Phase 1 | 2008-08-06 | |
NCT00000969 | HIV Infections | Drug: Zalcitabine|Drug: Didanosine | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Hoffmann-La Roche | 2013-09-28 | ||
NCT00001032 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2012-03-29 | |
NCT00000718 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine | National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche | 2012-03-28 | ||
NCT00002279 | HIV Infections | Drug: Zalcitabine | Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service | 2005-06-23 | ||
NCT00002086 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine|Drug: Interferon alfa-n1 | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 2 | 2005-06-23 | |
NCT00001022 | HIV Infections | Drug: Zidovudine|Drug: Zalcitabine|Drug: Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2013-09-28 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们